AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17346425 — intervention group
Group type: COMPARATOR
Intervention: Placebo (8 subjects)
Number of subjects: 20
Study 17346425 — intervention group
Group type: EXPERIMENTAL
Intervention: Reparixin
Number of subjects: 20
Study 15223899 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY720 0.25 mg
Number of subjects: 208
Study 15223899 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY720 0.5 mg
Number of subjects: 208
Study 15223899 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY720 1.0 mg
Number of subjects: 208
Study 15223899 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY720 2.5 mg
Number of subjects: 208
Study 15223899 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 208
Study 11812393 — intervention group
Group type: EXPERIMENTAL
Intervention: Repressors
Number of subjects: 41
Study 11812393 — intervention group
Group type: COMPARATOR
Intervention: 'Truly' low anxious participants
Number of subjects: 41
Study 11812393 — intervention group
Group type: COMPARATOR
Intervention: Moderately high anxious participants
Number of subjects: 41
Study 9569474 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of recombinant hepatitis B vaccine (10 micrograms or 20 micrograms of HBsAg per dose), administered 6 months apart
Number of subjects: 0
Study 9569474 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of vaccine given 2 years later
Number of subjects: 0
Study 7922851 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized colour vision tests (City University Colour Vision Test, Ishihara plates, American Optical Hardy‐Rand‐Rittler plates)
Number of subjects: 32
Study 7922851 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized colour vision tests
Number of subjects: 32
Study 2967032 — intervention group
Group type: EXPERIMENTAL
Intervention: methylprednisolone and chlorambucil for 6 months
Number of subjects: 39
Study 2967032 — intervention group
Group type: COMPARATOR
Intervention: untreated patients
Number of subjects: 39
Study 31428894 — intervention group
Group type: EXPERIMENTAL
Intervention: Rikkunshito (RKT) 7.5 g/day for 14 days
Number of subjects: 40
Study 31428894 — intervention group
Group type: COMPARATOR
Intervention: Control (no RKT)
Number of subjects: 40
Study 31428894 — intervention group
Group type: EXPERIMENTAL
Intervention: Rikkunshito (RKT)
Number of subjects: 40
Study 30321854 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized foot orthoses
Number of subjects: 72
Study 30321854 — intervention group
Group type: COMPARATOR
Intervention: Usual footwear (control)
Number of subjects: 72
Study 28615257 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron ingot
Number of subjects: 340
Study 28615257 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplement (18 mg/d)
Number of subjects: 340
Study 28615257 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 340
Study 28615257 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplement
Number of subjects: 340
Study 26033286 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg
Number of subjects: 369
Study 26033286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 369
Study 24151693 — intervention group
Group type: EXPERIMENTAL
Intervention: Video information
Number of subjects: 128
Study 24151693 — intervention group
Group type: COMPARATOR
Intervention: Verbal information
Number of subjects: 128
Study 20966119 — intervention group
Group type: EXPERIMENTAL
Intervention: New equations to estimate creatinine excretion rate (CER) with serum phosphorus
Number of subjects: 2466
Study 20966119 — intervention group
Group type: EXPERIMENTAL
Intervention: New equations to estimate creatinine excretion rate (CER) without serum phosphorus
Number of subjects: 2466
Study 20966119 — intervention group
Group type: COMPARATOR
Intervention: Existing equations to estimate creatinine excretion rate (CER)
Number of subjects: 2466
Study 18434157 — intervention group
Group type: EXPERIMENTAL
Intervention: fatigue of the plantar‐flexor muscles
Number of subjects: 10
Study 18434157 — intervention group
Group type: COMPARATOR
Intervention: no‐fatigue
Number of subjects: 10
Study 17000412 — intervention group
Group type: EXPERIMENTAL
Intervention: EYEPORT training (10 minutes per day, 6 days a week for 3 weeks)
Number of subjects: 31
Study 17000412 — intervention group
Group type: COMPARATOR
Intervention: No-train control condition (3 weeks)
Number of subjects: 31
Study 14551493 — intervention group
Group type: EXPERIMENTAL
Intervention: HRRV with no S/B but with prefeeding
Number of subjects: 731
Study 14551493 — intervention group
Group type: EXPERIMENTAL
Intervention: HRRV plus 1 of 3 different concentrations/volumes of S/B
Number of subjects: 731
Study 14551493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 731
Study 14551493 — intervention group
Group type: EXPERIMENTAL
Intervention: S/B vaccine groups
Number of subjects: 731
Study 10900525 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term individual dynamic psychotherapy (form 1)
Number of subjects: 144
Study 10900525 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term individual dynamic psychotherapy (form 2)
Number of subjects: 144
Study 10900525 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient ratings of the alliance and technique
Number of subjects: 144
Study 8823332 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) and fluorouracil (5-FU)
Number of subjects: 291
Study 8823332 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT), fluorouracil (5-FU), and mitomycin (MMC)
Number of subjects: 291
Study 8823332 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage chemoradiation (CR)
Number of subjects: 291
Study 1418102 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg twice daily
Number of subjects: 23
Study 1418102 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg twice daily
Number of subjects: 23
Study 1418102 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 80 mg twice daily
Number of subjects: 23
Study 1418102 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg twice daily
Number of subjects: 23
Study 1418102 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg twice daily
Number of subjects: 23
Study 1418102 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg twice daily
Number of subjects: 23
Study 1418102 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 23
Study 1418102 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 23
Study 3883879 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation
Number of subjects: 0
Study 3883879 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 0
Study 31182401 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported height, weight, and BMI
Number of subjects: 200
Study 31182401 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported waist circumference
Number of subjects: 200
Study 31182401 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported blood pressure (BP)
Number of subjects: 200
Study 31182401 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported hypertension classification
Number of subjects: 200
Study 31182401 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-measurements of BMI and diastolic BP
Number of subjects: 200
Study 29242283 — intervention group
Group type: EXPERIMENTAL
Intervention: BEZ235 400 mg twice daily
Number of subjects: 62
Study 29242283 — intervention group
Group type: COMPARATOR
Intervention: Everolimus 10 mg once daily
Number of subjects: 62
Study 27074806 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week multidisciplinary team care programme including a hand function treatment module
Number of subjects: 53
Study 27074806 — intervention group
Group type: COMPARATOR
Intervention: Regular care (control group)
Number of subjects: 53
Study 25022113 — intervention group
Group type: EXPERIMENTAL
Intervention: Jin's three-needle therapy (acupuncture)
Number of subjects: 66
Study 25022113 — intervention group
Group type: COMPARATOR
Intervention: Desloratadine oral suspension (5 mg once a day for 20 days)
Number of subjects: 66
Study 22545252 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nystatin 4 times/day for 14 days
Number of subjects: 40
Study 22545252 — intervention group
Group type: COMPARATOR
Intervention: Microwave denture disinfection (650 W for 3 minutes) 3 times/week for 14 days
Number of subjects: 40
Study 20673621 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervision
Number of subjects: 122
Study 20673621 — intervention group
Group type: EXPERIMENTAL
Intervention: No supervision
Number of subjects: 122
Study 20673621 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 122
Study 17400142 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong
Number of subjects: 20
Study 16264158 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV DNA testing with cryotherapy for positive HPV results
Number of subjects: 6555
Study 16264158 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual inspection with acetic acid (VIA) with cryotherapy for positive VIA results
Number of subjects: 6555
Study 16264158 — intervention group
Group type: COMPARATOR
Intervention: Delayed evaluation (control group)
Number of subjects: 6555
Study 11876709 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication treatment (1-week omeprazole-based triple therapy, followed by 7-week omeprazole)
Number of subjects: 40
Study 11876709 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole alone (8-week omeprazole)
Number of subjects: 40
Study 11876709 — intervention group
Group type: COMPARATOR
Intervention: Uninfected patients (control group)
Number of subjects: 40
Study 10453583 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture with vibrating shallow insertion
Number of subjects: 80
Study 10453583 — intervention group
Group type: COMPARATOR
Intervention: Conventional electroacupuncture method
Number of subjects: 80
Study 8800852 — intervention group
Group type: EXPERIMENTAL
Intervention: Central one third patellar tendon
Number of subjects: 10
Study 8800852 — intervention group
Group type: COMPARATOR
Intervention: Residual patellar tendon
Number of subjects: 10
Study 2184527 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination tablet (RHZ), 5 tablets per day on weekdays for 100 treatment-days
Number of subjects: 150
Study 2184527 — intervention group
Group type: COMPARATOR
Intervention: Four-drug regimen (RHZS) (streptomycin, rifampicin, isoniazid and pyrazinamide)
Number of subjects: 150
Study 376950 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment 1: Actinomycin-D (Act-D), 0.01 mg/kg IV, days 1-5; L-PAM, 4 mg PO, days 1-10 every six weeks
Number of subjects: 144
Study 376950 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment 2: Act-D, 0.01 mg/kg IV, days 1-5; L-PAM, 4 mg PO, days 1-10; Vincristine, 1 mg IV, days 1, 8, 15, 22, 29, 36, repeat every six weeks
Number of subjects: 144
Study 376950 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment 3: Act-D, 0.01 mg/kg IV, days 1-5; L-PAM, 4 mg PO, days 1-10; NSC-1026, 200 mg/kg IV, days 1-6
Number of subjects: 144
Study 376950 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment 4: Adriamycin, 0.4 mg/kg IV, days 1, 2, 3, 8, 9, 10, then 2XWK starting day 15 (max. 1,200 mg)
Number of subjects: 144
Study 30503506 — intervention group
Group type: EXPERIMENTAL
Intervention: TMS-EEG in MDD participants
Number of subjects: 30
Study 30503506 — intervention group
Group type: COMPARATOR
Intervention: TMS-EEG in healthy participants
Number of subjects: 30
Study 28366181 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA + quercetin (190 mg/d)
Number of subjects: 67
Study 28366181 — intervention group
Group type: COMPARATOR
Intervention: ALA + placebo (3.3 g/d ALA)
Number of subjects: 67
Study 25630055 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoblock MAD
Number of subjects: 45
Study 25630055 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin block MAD
Number of subjects: 45
Study 23343489 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy for late-life depression
Number of subjects: 22
Study 21760724 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg PO once daily for 5 days)
Number of subjects: 0
Study 21760724 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanic acid (875/125 mg PO twice daily for 7 days)
Number of subjects: 0
Study 19843742 — intervention group
Group type: EXPERIMENTAL
Intervention: 64-MDCT with oral and IV contrast media (Group 1)
Number of subjects: 303
Study 19843742 — intervention group
Group type: COMPARATOR
Intervention: 64-MDCT with IV contrast material only (Group 2)
Number of subjects: 303
Study 17426111 — intervention group
Group type: EXPERIMENTAL
Intervention: Triiodothyronine (T(3)) infusion for 24 hours after surgery
Number of subjects: 0
Study 17426111 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion for 24 hours after surgery
Number of subjects: 0
Study 15553821 — intervention group
Group type: EXPERIMENTAL
Intervention: Shengxuening (SXN) 0.1 g, three times per day for 30 days
Number of subjects: 100
Study 15553821 — intervention group
Group type: COMPARATOR
Intervention: Ferrous gluconate 0.1 g, three times per day for 30 days
Number of subjects: 100
Study 11439409 — intervention group
Group type: EXPERIMENTAL
Intervention: m‐CPP (meta‐chlorophenylpiperazine)
Number of subjects: 12
Study 11439409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11439409 — intervention group
Group type: EXPERIMENTAL
Intervention: m‐CPP
Number of subjects: 12
Study 9800078 — intervention group
Group type: EXPERIMENTAL
Intervention: Groningen voice prosthesis
Number of subjects: 0
Study 9800078 — intervention group
Group type: EXPERIMENTAL
Intervention: Nijdam voice prosthesis
Number of subjects: 0
Study 9800078 — intervention group
Group type: EXPERIMENTAL
Intervention: Provox voice prosthesis
Number of subjects: 0
Study 9800078 — intervention group
Group type: COMPARATOR
Intervention: Groningen, Nijdam, and Provox voice prostheses
Number of subjects: 0
Study 7972781 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose acetylsalicylic acid (25 mg) and dipyridamole (200 mg) (ASAD) twice daily for 1 year
Number of subjects: 160
Study 7972781 — intervention group
Group type: COMPARATOR
Intervention: Oral anticoagulants
Number of subjects: 160
Study 7972781 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose acetylsalicylic acid (25 mg) and dipyridamole (200 mg) (ASAD)
Number of subjects: 160
Study 2685207 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (specific dosage and duration not mentioned)
Number of subjects: 680
Study 2685207 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (no specific intervention mentioned)
Number of subjects: 680
Study 2685207 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients receiving antidepressants at the time of assessment (specific treatment not mentioned)
Number of subjects: 680
Study 2685207 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment initiated after assessment (specific treatment not mentioned)
Number of subjects: 680
Study 48731 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased exposure to sunlight during the hot season
Number of subjects: 91
Study 48731 — intervention group
Group type: COMPARATOR
Intervention: Cold season group (control)
Number of subjects: 91
Study 31625835 — intervention group
Group type: EXPERIMENTAL
Intervention: Omr‐IgG‐am
Number of subjects: 62
Study 31625835 — intervention group
Group type: COMPARATOR
Intervention: IVIG
Number of subjects: 62
Study 31625835 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 62
Study 28454872 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (received crash alerts)
Number of subjects: 40
Study 28454872 — intervention group
Group type: COMPARATOR
Intervention: Control group (never received warnings)
Number of subjects: 40
Study 25636410 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized homeopathy
Number of subjects: 60
Study 25636410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 23139093 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent monitoring of ScvO2
Number of subjects: 106
Study 23139093 — intervention group
Group type: COMPARATOR
Intervention: Continuous monitoring of ScvO2
Number of subjects: 106
Study 22269198 — intervention group
Group type: EXPERIMENTAL
Intervention: Single session filling without calcium hydroxide medication
Number of subjects: 20
Study 22269198 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide-based intracanal medication Calen®
Number of subjects: 20
Study 19563586 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 LD(50) units/kg total body weight of BoNT‐A injected into gastrocnemius muscles every 4 months
Number of subjects: 214
Study 19563586 — intervention group
Group type: COMPARATOR
Intervention: 30 LD(50) units/kg total body weight of BoNT‐A injected into gastrocnemius muscles once yearly
Number of subjects: 214
Study 18062111 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue-engineered mucosal graft
Number of subjects: 9
Study 18062111 — intervention group
Group type: COMPARATOR
Intervention: Periosteal fenestration technique
Number of subjects: 9
Study 12631443 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antioxidative treatment (Quatral) once daily for 16 weeks
Number of subjects: 74
Study 12631443 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 74
Study 10698386 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (12 mg intravenously)
Number of subjects: 40
Study 10698386 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 40
Study 9329380 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/day)
Number of subjects: 33
Study 9329380 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen (hormone replacement therapy)
Number of subjects: 33
Study 9329380 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 33
Study 7870919 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.5 g/l)
Number of subjects: 8
Study 7870919 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol + Diazepam (5 mg)
Number of subjects: 8
Study 7870919 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg)
Number of subjects: 8
Study 7870919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2874958 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 60
Study 2874958 — intervention group
Group type: COMPARATOR
Intervention: Clemastine
Number of subjects: 60
Study 2874958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 30359870 — intervention group
Group type: EXPERIMENTAL
Intervention: Anteroposterior (AP) shoulder joint mobilization
Number of subjects: 31
Study 30359870 — intervention group
Group type: COMPARATOR
Intervention: Manual contact
Number of subjects: 31
Study 30359870 — intervention group
Group type: COMPARATOR
Intervention: No-contact intervention
Number of subjects: 31
Study 27545673 — intervention group
Group type: EXPERIMENTAL
Intervention: Active-approach messages
Number of subjects: 0
Study 27545673 — intervention group
Group type: EXPERIMENTAL
Intervention: Active-avoidance messages
Number of subjects: 0
Study 27545673 — intervention group
Group type: COMPARATOR
Intervention: Less active behavior messages
Number of subjects: 0
Study 24964745 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Antiphospholipid Syndrome Score (GAPSS)
Number of subjects: 51
Study 24964745 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 51
Study 24964745 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in GAPSS
Number of subjects: 51
Study 24964745 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in GAPSS by 3 or more points
Number of subjects: 51
Study 23356032 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (control group)
Number of subjects: 0
Study 23356032 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment lasting six months (intervention group)
Number of subjects: 0
Study 19482961 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximity to nutrient-dense food
Number of subjects: 46
Study 19482961 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximity to energy-dense food
Number of subjects: 46
Study 19482961 — intervention group
Group type: COMPARATOR
Intervention: Sitting farther away from food
Number of subjects: 46
Study 19020698 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual lymphatic drainage supplemented by Deep Oscillation (n=11)
Number of subjects: 21
Study 19020698 — intervention group
Group type: COMPARATOR
Intervention: Manual lymphatic drainage alone (n=10)
Number of subjects: 21
Study 15593392 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous transfusion (Group A)
Number of subjects: 60
Study 15593392 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic transfusion (Group H)
Number of subjects: 60
Study 15593392 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Group A and Group H
Number of subjects: 60
Study 12885982 — intervention group
Group type: EXPERIMENTAL
Intervention: Buteyko breathing technique
Number of subjects: 90
Study 12885982 — intervention group
Group type: COMPARATOR
Intervention: Pink City Lung Exerciser (PCLE)
Number of subjects: 90
Study 12885982 — intervention group
Group type: COMPARATOR
Intervention: PCLE placebo device
Number of subjects: 90
Study 10393392 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral isosorbide-5-mononitrate (ISMN) 50 mg once daily
Number of subjects: 136
Study 10393392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 8697554 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine alone (phase M)
Number of subjects: 0
Study 8697554 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administration of ketamine (1.0 mg) with morphine (phase M + K)
Number of subjects: 0
Study 8697554 — intervention group
Group type: COMPARATOR
Intervention: Control group (phase M)
Number of subjects: 0
Study 1992660 — intervention group
Group type: EXPERIMENTAL
Intervention: DFO 40 mg/kg
Number of subjects: 12
Study 1992660 — intervention group
Group type: EXPERIMENTAL
Intervention: DFO 80 mg/kg
Number of subjects: 12
Study 1992660 — intervention group
Group type: EXPERIMENTAL
Intervention: DFO (both doses)
Number of subjects: 12
Study 1992660 — intervention group
Group type: EXPERIMENTAL
Intervention: DFO once a week
Number of subjects: 12